Project Grant R01DA059573

Award Date 7/15/24
Completion Date 6/30/27
Dollars Obligated $1.5M
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.077
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06519, USA
Similar Awards
The National Institutes of Health (NIH) Office of the Director awarded a $1,197,896 Project Grant under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) to the University of Oklahoma Health Sciences Center. The objective of this 5-year longitudinal study is to use traditional survey methods combined with ecological momentary assessment (EMA) to better understand the impact of electronic nicotine delivery system (ENDS) product characteristics on...
This Project Grant award of $515,632 from the National Cancer Institute's (NCI) Cancer Cause and Prevention Research program (CFDA 93.393) supports research to prepare the U.S. and state governments for the potential implementation of two cigarette product standards by the FDA - a menthol ban and a nicotine reduction standard. The key objectives are to: 1) Estimate for each U.S. state the increase in people who smoke that would quit and enroll in quit lines following the implementation of...
This Project Grant award of $3,257,011 from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will fund a randomized controlled trial to evaluate the effectiveness of switching to electronic nicotine delivery systems (ENDS) compared to nicotine replacement therapy (NRT) for promoting smoking abstinence among individuals enrolled in substance use disorder (SUD) treatment programs in South Carolina. The study aims to: 1) assess...
This Project Grant award of $622,957 from the National Institutes of Health (NIH) Office of the Director, under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077), supports research by Duke University to investigate the chemical composition and behavioral effects of novel tobacco products, including oral nicotine pouches and "non-menthol" cigarettes. The study aims to analyze the flavors, sweeteners, and nicotine forms in these products, and...
This $773,359 federal Project Grant award, funded by the National Institutes of Health (NIH) under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077), will support a randomized controlled trial to evaluate the effectiveness of nicotine pouches as a cigarette substitute. The University of Wisconsin-Madison will conduct this 5-year research study to assess how readily smokers will adopt nicotine pouches, how effectively pouches can substitute for...
This $3,230,000 Project Grant awarded by the National Institutes of Health (NIH) Office of the Director under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) supports research to investigate the cardiovascular effects of dual use of tobacco and nicotine delivery products, such as cigarettes and e-cigarettes. The project, awarded to the University of California, San Francisco (UCSF), aims to: (1) understand the cardiovascular health effects of...
This Project Grant award from the National Institutes of Health's Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) provides $549,555.45 to The Trustees of the University of Pennsylvania to investigate the exposure and respiratory health effects of chemical constituents from electronic cigarette (e-cigarette) use among young adults. The project aims to: 1) evaluate the relationship between e-cigarette use and exposure to metals and aldehydes, 2) assess...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $265,239 to the University of North Carolina at Chapel Hill to conduct research on the effects of vaping-induced oxidation on nicotine analogs, such as 6-methyl nicotine, used in e-cigarettes. The key objectives are to: 1) analyze the chemical composition and metabolism of 6-methyl nicotine and nicotinamide vaping devices before and after...
The National Institutes of Health (NIH), through the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077), awarded a $669,321 project grant to the Regents of the University of California at Riverside (UC Riverside). The grant supports a 1-year study to characterize new and emerging ingredients, acids, toxicants, and indicators of non-tobacco nicotine in electronic cigarette (e-cigarette) products. The research will involve: Analyzing 600 commercial...
This $310,319 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support the University of Louisville in conducting formative research to develop a motivation-based adolescent vaping typology to inform the development of tailored cognitive behavioral e-cigarette cessation interventions. The key objectives are to: 1) identify different types of adolescent e-cigarette users based on their motivations for use, 2)...

USING NOVEL LABELING TO IMPROVE PUBLIC UNDERSTANDING OF NICOTINE IN ELECTRONIC NICOTINE DELIVERY SYSTEMS (ENDS): NICOTINE CONCENTRATION AND NICOTINE FLUX - PROJECT SUMMARY USE OF ELECTRONIC NICOTINE DELIVERY SYSTEMS (ENDS) CAN HAVE POSITIVE AND NEGATIVE EFFECTS ON PUBLIC HEALTH. IDEALLY, PEOPLE WHO SMOKE WOULD SWITCH TO ENDS, AND VULNERABLE POPULATIONS LIKE YOUTH WOULD AVOID ENDS ALTOGETHER. YET, MOST ADULTS WHO USE ENDS ALSO SMOKE, AND ENDS HAVE BEEN THE MOST POPULAR NICOTINE PRODUCT AMONG YOUTH SINCE 2014. EFFECTIVE INFORMATIONAL LABELS FOR THE NICOTINE STRENGTH OF ENDS COULD HELP TO ADDRESS THESE PROBLEMS. FOR SMOKERS WHO WANT TO SWITCH TO ENDS, EASILY SELECTING A PRODUCT WITH SUFFICIENT NICOTINE TO FACILITATE A COMPLETE SWITCH IS CRITICAL. FOR YOUTH, INFORMATIVE LABELS MAY DETER ENDS UPTAKE, USE OF HIGH-NICOTINE ENDS, AND DEVELOPMENT OF NICOTINE DEPENDENCE. THE FDA REQUIRES NICOTINE CONCENTRATION LABELS ON ENDS, TYPICALLY IN MG/ML OR PERCENT, BUT NEITHER YOUTH NOR ADULTS UNDERSTAND THESE METRICS. WE PREVIOUSLY PILOT TESTED NEW NICOTINE CONCENTRATION LABELS THAT IMPROVED ENDS USERS' ABILITY TO INTERPRET THE STRENGTH AND ADDICTIVENESS OF NICOTINE IN ENDS. HERE, WE PROPOSE TO EXTEND OUR WORK TO DEVELOP TWO LABELS: 1) A NICOTINE CONCENTRATION LABEL THAT COULD REPLACE ALL CURRENT FDA-REQUIRED ENDS NICOTINE CONCENTRATION LABELS, AND 2) A NOVEL, POTENTIALLY MORE INFORMATIVE LABEL FOR NICOTINE EMISSIONS ("FLUX") FROM POPULAR CLOSED-SYSTEM DEVICES LIKE VUSE AND JUUL. IN AIM 1, WE WILL REFINE OUR PILOTED NICOTINE CONCENTRATION LABEL BY RE-ANCHORING THE NICOTINE STRENGTH CATEGORIES ON THE LABEL (E.G., MEDIUM, HIGH) TO THE NICOTINE CONTENT IN CIGARETTES. WE ALSO WILL DEVELOP NICOTINE FLUX LABELS FOR CLOSED-SYSTEM ENDS, WHICH HAVE FIXED, CALCULATABLE NICOTINE EMISSIONS; ARE THE MOST POPULAR DEVICE TYPE; AND ARE THE ONLY DEVICE TYPE TO RECEIVE FDA APPROVAL FOR SALES IN THE UNITED STATES. FLUX, THE RATE OF NICOTINE EMISSIONS FROM ENDS, BETTER APPROXIMATES NICOTINE DELIVERY THAN CONCENTRATION ALONE. WE WILL EMPLOY QUALITATIVE METHODS (I.E., EXPERT FEEDBACK, FOCUS GROUPS) TO IDENTIFY THE OPTIMAL SCALING FOR OUR CONCENTRATION LABEL AND TO DETERMINE KEY FEATURES FOR INCLUSION ON OUR FLUX LABELS. IN AIM 2, WE WILL COMPARE THE MG/ML MARKET LABEL (THE TOP-PERFORMING MARKET LABEL FROM OUR PRIOR WORK), OPTIMIZED NICOTINE CONCENTRATION LABEL, AND FLUX LABELS. WE WILL SURVEY 2,000 YOUTH AND ADULTS WHO USE ENDS, CIGARETTES, OR NO TOBACCO PRODUCTS TO COMPARE THE ABILITY OF OUR NEW LABELS TO ACCURATELY CONVEY ENDS NICOTINE STRENGTH RELATIVE TO CURRENT MARKET LABELING AND TO EACH OTHER. WE ALSO WILL ASSESS PERCEIVED ADDICTIVENESS, PERCEIVED LABEL UTILITY, AND PRODUCT USE INTENTIONS. WE EXPECT THE NEW CONCENTRATION AND FLUX LABELS TO MORE ACCURATELY CONVEY ENDS NICOTINE STRENGTH THAN MG/ML ALONE. WE ALSO EXPECT THE NEW LABELS TO BETTER CONVEY INFORMATION ABOUT ADDICTIVENESS, TO BE RATED AS HAVING MORE UTILITY THAN MG/ML, TO DECREASE USE INTENTIONS AMONG NEVER USERS, AND TO INCREASE INTENTIONS TO USE ENDS IN A QUIT SMOKING ATTEMPT. PROJECT FINDINGS WILL PROVIDE THE FDA A SUPERIOR ALTERNATIVE TO CURRENT NICOTINE CONCENTRATION LABELS FOR ALL ENDS AND WILL INDICATE IF NICOTINE FLUX LABELING HAS ADDED BENEFIT FOR THE MOST POPULAR ENDS DEVICE TYPE: CLOSED-SYSTEM ENDS. IN SUM, THE PROPOSED PROJECT WILL INCREASE PUBLIC UNDERSTANDING OF NICOTINE CONCENTRATIONS OF ALL ENDS AND NICOTINE EMISSIONS FROM CLOSED-SYSTEM ENDS.

Posted 7/3/24